EXEL Stock Analysis: Buy, Sell, or Hold?
EXEL - Exelixis Inc
$55.06
2.03 (3.83%)
▲
5d:
-1.34%
30d:
-1.41%
90d:
+26.05%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Smart Money Distribution
None View Scanner →
Strength: 6.7/10
Get Alerted When EXEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EXEL shows positive signals but monitor for confirmation. Market pricing in 3.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: EXEL shows positive signals but monitor for confirmation. Market pricing in 3.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$77.92
Based on 9.3% avg growth
INTRINSIC VALUE TODAY
$48.38
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXEL is currently trading at $55.06, which is considered fair relative to its 30-day fair value range of $54.47 to $56.43. The stock's valuation (Forward PE: 13.6) is in line with its historical norms (12.4). At these levels, the market is pricing in 3.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EXEL is in a strong uptrend. Immediate support is located at $52.32, while resistance sits at $56.85. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EXEL is in a strong uptrend. Immediate support is located at $52.32, while resistance sits at $56.85. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$54.47 -
$56.43
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BEARISH: Trading above Wall St target ($52.07)
- NEUTRAL: Market pricing in 3.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$54.47 -
$56.43
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$52.32
Resistance Level
$56.86
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.60
Wall Street Target
$52.07
(-5.4%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
43.6%
Profit Margin
35.1%
Valuation Premium vs History
+3.2% premium
PE vs Historical
13.6 vs 12.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.2%
(market-implied from PE analysis)
1-Year Target
$56.82
(+3%)
2-Year Target
$58.64
(+7%)
3-Year Target
$60.52
(+10%)
3-Yr Target (if PE normalizes)
(PE: 14→12)
PE COMPRESSION
$55.19
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 14.5%)
$126.11
(+129%)
Base:
(SPY PE: 13.6, Growth: 14.5%)
$82.72
(+50%)
Bear:
(PE: 11.6, Growth: 14.5%)
$70.31
(+28%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.53 | Current EPS (TTM): $3.02
Bull Case
$82.55
(+56%)
Analyst growth 34.1%, PE expands to 20.4
Base Case
$75.05
(+42%)
Market implied 34.1%, PE stable at 18.5
Bear Case
$38.06
(-28%)
Severe decline -20.0%, PE contracts to 15.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 03, 2026 5:49 PM ET
Data refreshes hourly during market hours. Next update: 6:49 PM
Data refreshes hourly during market hours. Next update: 6:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Dana Aftab
SELL
47918 shares
2026-02-24
Dana Aftab
SELL
29873 shares
2026-02-19
Brenda Hefti
SELL
18669 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
Advanced EXEL Option Strategies
Professional options setups generated by AI based on today's EXEL price and gamma walls.
